Research Project
Grant-in-Aid for Scientific Research (B)
PEG is considered as non-toxic and non-immunogenic material, and surface modification with it can improve the immunogenicity and pharmacokinetics of nanocarriers. However, we reported that PEGylated liposome (SL), which has been approved for clinical use, loses their long circulating properties when they are administered twice in same animal with certain interval (accelerated blood clearance (ABC) phenomenon). We elucidated that anti-PEG IgM, secreted in response to the first dose of SL, is responsible for the rapid clearance of the second dose via initiation of complement activation. We further elucidated that such anti-PEG IgM production is caused in nude mice (no T-cells), while it was not caused in SCID mice (no B and T cells) and splenectomized mice (no spleen). These suggest that spleen B cells produce the anti-PEG IgM in a T-cell independent manner. It appears that SL activates the immunity in spleen as T-cell independent antigens do. Our studies clearly demonstrate that any PEGylated formulations may display unexpected pharmacokinetic behavior upon repeated injection if such formulation induce anti-PEG IgM production and, as a consequence, may show less therapeutic efficacy or even cause undesirable side-effects. Therefore, a strategy to abrogate the immunogenicity of PEGylated formulations without significant compromising their in vivo performance would be highly desirable for the further development of promising PEGylated formulations.
All 2011 2010 2009 2008 Other
All Journal Article (24 results) (of which Peer Reviewed: 24 results) Presentation (30 results) Book (1 results) Remarks (1 results)
Pharmaceutics in press
J.Control.Release in press
Pharmaceutics
Volume: (in press)
J.Control.Release
Biomacromolecules 11
Pages: 2700-2706
Biol.Pharm.Bull. 25
Pages: 149-154
130000322353
Int.J.Pharm. 392
Pages: 218-223
J.Control.Release 142
Pages: 160-166
Biomacromolecules
Volume: 11 Pages: 2700-2706
Biol.Pharm.Bull.
Volume: 25 Pages: 149-154
Int.J.Pharm.
Volume: 392 Pages: 218-223
Volume: 142 Pages: 160-166
Int.J.Pharm. (In press)
Pharm.Res. 26
Pages: 2270-2279
J.Control.Release 137
Pages: 234-240
Int.J.Pharm. 362
Pages: 197-200
J.Control.Release 126
Pages: 162-165
Int.J.Pharm. 354
Pages: 56-62
Pharm. Res. 25
Pages: 2497-2504
Int. J. Pharm. 362
J. Control. Release 126
http://www.ph.tokushima-u.ac.jp/article/0015027.html